U.S. markets closed

Vaxxinity, Inc. (VAXX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
8.82-0.53 (-5.67%)
At close: 04:00PM EST
8.82 0.00 (0.00%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close9.35
Bid8.57 x 800
Ask9.10 x 800
Day's Range8.47 - 9.82
52 Week Range8.47 - 22.77
Avg. Volume703,912
Market Cap1.171B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.17
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for VAXX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Vaxxinity, Inc.
    Daily – Vickers Top Buyers & Sellers for 12/01/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • Motley Fool

    Vaxxinity Has a Rough Public Debut

    In this Motley Fool Live video recorded on Nov. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss the prospects for the company's experimental COVID-19 vaccine and its Alzheimer's disease therapy. Given how late Vaxxinity is to the COVID-19 vaccine enterprise, the history of failures in developing therapies for Alzheimer's disease, and the fact that the company's most advanced programs are phase 2 clinical studies, it's not surprising that there isn't as much investor interest as initially hoped for.

  • GlobeNewswire

    Vaxxinity Announces Closing of IPO and Partial Exercise of Underwriters’ Option to Purchase Additional Shares

    DALLAS, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced the closing of its initial public offering of 6,000,000 shares of class A common stock at a public offering price of $13.00 per share on November 15, 2021 as well as the subsequent closing on November 18, 2021 of the issuance of an additional 537,711 shares of class A common stock, pursuant to a 30-day option granted to t

  • Benzinga

    Vaxxinity Insider Makes $240K Stock Purchase

    Mei Mei Hu, Insider at Vaxxinity (NASDAQ:VAXX), made a large insider buy on November 15, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Hu exercised options to purchase 4,748,700 shares of Vaxxinityat prices ranging from ($0.00) to $13.82. The total transaction amounted to $241,920. Following the transaction, Hu now owns 3,973,012 shares of Vaxxinity, worth $68,017,965. Vaxxinity shares are trading up 7.0% at $